Hemiballismus (also known as hemiballism) is a rare movement disorder characterized by sudden, violent, involuntary flinging or throwing movements of one side of the body. The term derives from the Greek words "hemi-" (half), "ballismos" (to throw), and describes one of the most dramatic hyperkinetic movement disorders in neurology.
- Sudden onset: Movements typically begin abruptly without warning
- Unilateral involvement: Affects arm and leg on the same side (contralateral to the lesion)
- Movement characteristics:
- Rapid, random, and purposeless
- Large-amplitude flinging motions
- Can be continuous or episodic
- Often worsen with attempted voluntary movement
- May decrease during sleep
- Motor dysfunction: Significant impairment of voluntary movement due to constant involuntary activity
- Psychological impact: Anxiety, frustration, and depression due to disabling movements
- Risk of injury: Patients may harm themselves due to violent movements
- Huntington's disease - Most common cause of hemiballismus in the context of neurodegeneration
- Wilson disease - Copper accumulation affecting the basal ganglia
- Multiple system atrophy - Autonomic and movement disorder syndrome
- C9orf72 expansion - Associated with ALS/FTD spectrum
- Stroke (most common etiology) - Ischemic or hemorrhagic lesions affecting the:
- Subthalamic nucleus
- Striatum (putamen, caudate)
- Globus pallidus
- Brain tumors
- Traumatic brain injury
- Multiple sclerosis plaques
- Non-ketotic hyperglycemia - Increasingly recognized cause, particularly in elderly
- Hypoglycemia
- Thyroid dysfunction
- Drug-induced:
- Antiparkinsonian medications (levodopa)
- Anticonvulsants (phenytoin)
- Neuroleptics (tardive dyskinesia)
- Systemic lupus erythematosus
- CNS vasculitis
- Autoimmune encephalitis
The basal ganglia motor circuit normally functions to:
- Initiate desired movements
- Inhibit competing/involuntary movements
flowchart TD
A["Subthalamic Nucleus Lesion"] --> B["Loss of STN Excitatory Output"]
B --> C["Reduced GPi Activity"]
C --> D["Thalamic Disinhibition"]
D --> E["Excessive Thalamocortical Drive"]
E --> F["Involuntary Ballistic Movements"]
F --> G["Contralateral Hemiballismus"]
A --> H["Stroke / Hemorrhage / Tumor"]
- STN lesion/disruption → Loss of excitatory drive to GPi
- GPi hypoactivity → Reduced inhibition of thalamocortical pathways
- Thalamocortical overactivity → Excessive, uncontrolled movements
The subthalamic nucleus plays a critical role in modulating basal ganglia output. Damage to this structure or its connections leads to disinhibition of thalamocortical projections, resulting in the characteristic ballistic movements.
- Acute or subacute onset of unilateral violent movements
- Movements are continuous, random, and high-amplitude
- Affects arm and leg on same side
- Excluding other causes through history and imaging
- MRI brain: Identify structural lesions (stroke, tumor, MS plaques)
- CT brain: Acute hemorrhage detection
- PET/SPECT: Metabolic changes in basal ganglia
- Metabolic panel: Glucose, electrolytes, liver function
- Copper studies: Ceruloplasmin, 24-hour urine copper (ruling out Wilson disease)
- Autoimmune screening: ANA, anti-dsDNA, antiphospholipid antibodies
- Genetic testing: Huntington disease gene testing when indicated
- Exclude infectious causes
- Oligoclonal bands (for MS)
- Autoantibody testing
-
Dopamine receptor blockers (first-line):
- Haloperidol: 1-10 mg/day
- Olanzapine: 5-20 mg/day
- Risperidone: 1-6 mg/day
-
Benzodiazepines:
- Clonazepam: 0.5-3 mg/day
- Diazepam: 5-20 mg/day
-
Tetrabenazine: 12.5-200 mg/day (depletes dopamine)
-
Valproic acid: 500-2000 mg/day
-
Levetiracetam: 1000-3000 mg/day
- Stroke: Secondary prevention
- Wilson disease: Chelation therapy (penicillamine, trientine)
- Metabolic: Glucose control, thyroid replacement
- Autoimmune: Immunomodulation
- Deep brain stimulation (DBS):
- Target: Globus pallidus interna (GPi)
- Effective in medication-refractory cases
- Significant reduction in ballistic movements reported
- Physical therapy for injury prevention
- Occupational therapy for functional adaptation
- Psychological support
- Identified and treatable underlying cause
- Early intervention
- Younger age
- Metabolic etiology (often reversible)
- Neurodegenerative etiology (progressive)
- Structural lesions (stroke, tumor)
- Delayed treatment
- Bilateral involvement (rare)
- Post-stroke: Often improves over weeks to months as lesion resolves
- Metabolic: Usually resolves with correction of underlying abnormality
- Neurodegenerative: Often persistent, may require chronic management
Hemiballismus can be a presenting feature in Huntington disease, particularly in juvenile-onset cases with CAG repeat expansions.
Copper accumulation in the basal ganglia can present with hemiballismus. See Wilson's disease treatment for management protocols.
Parkinsonian variant (MSA-P) can present with ballistic movements in some cases.
- Gene therapy approaches for Huntington disease
- Novel dopaminergic agents
- Immunomodulatory treatments for autoimmune causes
- Antisense oligonucleotides for genetic causes
- Cell replacement therapies under investigation
- Novel DBS protocols with adaptive stimulation
Emerging Treatment Approaches:
- Recent studies have explored immunomodulatory therapies for autoimmune-related hemiballismus, showing promise in case series
- Novel dopamine receptor antagonists with improved side effect profiles are under investigation for acute ballistic movements
Genetics and Biomarkers:
- Next-generation sequencing has identified new genetic variants associated with secondary hemiballismus
- Neuroimaging biomarkers using MRI tractography help predict outcomes in STN lesions
References